Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.

Daraxonrasib 是一种泛 RAS 抑制剂，它通过阻断 AKT 信号传导和基质金属蛋白酶活性，选择性地抑制 KRAS 激活的骨肉瘤